Comparison of SCH 486757 to Codeine and Placebo in Subjects With Persistent Postviral Cough (Study P03069AM2)(COMPLETED)
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This randomized, multicenter, parallel-group, double-blind, double-dummy, placebo- and
active-controlled study will evaluate the efficacy and safety of SCH 486757 in subjects with
persistent cough resulting from a recent viral upper respiratory infection (URI). The primary
objective is to assess the efficacy of SCH 486757 administered at a dose of 100 mg twice
daily for 5 days in the reduction of cough severity score compared with placebo. The key
secondary objective is to evaluate the reduction in the number of coughs with SCH 486757
compared with placebo. Because codeine is a widely used as a cough medication, it is included
as a treatment arm in the study.